share_log

Hims & Hers Health | 10-Q: Q2 2024 Earnings Report

Hims & Hers Health | 10-Q: Q2 2024 Earnings Report

Hims & Hers Health | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/05 16:18

Moomoo AI 已提取核心訊息

Hims & Hers Health reported strong financial results for Q2 2024, with total revenue increasing 52% year-over-year to $315.6 million. Online Revenue grew 53% to $306.8 million, driven by a 43% increase in subscribers to 1.9 million. The company achieved net income of $13.3 million, compared to a net loss of $7.2 million in Q2 2023, while Adjusted EBITDA reached $39.3 million with a 12% margin.The company demonstrated robust operational execution with Monthly Online Revenue per Average Subscriber increasing to $57, up from $53 in Q2 2023. Average Order Value grew 27% to $121, benefiting from newer offerings and longer duration subscriptions. Gross margin remained healthy at 81%, while operating expenses as a percentage of revenue improved to 78% from 86% last year.Looking ahead, Hims & Hers announced plans to acquire a 503B compounding outsourcing facility for approximately $31 million to expand its compounding capabilities. The Board also authorized a new $100 million share repurchase program through August 2027, following the completion of its previous $50 million program.
Hims & Hers Health reported strong financial results for Q2 2024, with total revenue increasing 52% year-over-year to $315.6 million. Online Revenue grew 53% to $306.8 million, driven by a 43% increase in subscribers to 1.9 million. The company achieved net income of $13.3 million, compared to a net loss of $7.2 million in Q2 2023, while Adjusted EBITDA reached $39.3 million with a 12% margin.The company demonstrated robust operational execution with Monthly Online Revenue per Average Subscriber increasing to $57, up from $53 in Q2 2023. Average Order Value grew 27% to $121, benefiting from newer offerings and longer duration subscriptions. Gross margin remained healthy at 81%, while operating expenses as a percentage of revenue improved to 78% from 86% last year.Looking ahead, Hims & Hers announced plans to acquire a 503B compounding outsourcing facility for approximately $31 million to expand its compounding capabilities. The Board also authorized a new $100 million share repurchase program through August 2027, following the completion of its previous $50 million program.
Hims & HERS Health在2024年第二季度發佈了強勁的財務業績，營業收入同比增長52%，達到31560萬美元。在線收入增長53%，達到30680萬美元，這得益於訂閱用戶數增加43%至190萬。公司實現了凈利潤1330萬美元，而2023年第二季度淨虧損爲720萬美元，同時調整後的息稅折舊攤銷前利潤（EBITDA）達到了3930萬美元，毛利率爲12%。公司在運營執行方面表現優異，平均每位訂閱用戶的每月在線收入增加到57美元，高於2023年第二季度的53美元。平均訂單價值增長27%，達到121美元，受益於新產品推出和較長的訂閱週期。毛利率保持在健康的81%，而營業費用佔營業收入的比例從去年的86%改善至78%。展望未來，Hims & HERS宣佈計劃以大約3100萬美元收購一個5030億美元的複合外包設施，以擴展其複合能力。董事會還授權了一項新的10000萬美元股票回購計劃，持續到2027年8月，此前完成了5000萬美元的計劃。
Hims & HERS Health在2024年第二季度發佈了強勁的財務業績，營業收入同比增長52%，達到31560萬美元。在線收入增長53%，達到30680萬美元，這得益於訂閱用戶數增加43%至190萬。公司實現了凈利潤1330萬美元，而2023年第二季度淨虧損爲720萬美元，同時調整後的息稅折舊攤銷前利潤（EBITDA）達到了3930萬美元，毛利率爲12%。公司在運營執行方面表現優異，平均每位訂閱用戶的每月在線收入增加到57美元，高於2023年第二季度的53美元。平均訂單價值增長27%，達到121美元，受益於新產品推出和較長的訂閱週期。毛利率保持在健康的81%，而營業費用佔營業收入的比例從去年的86%改善至78%。展望未來，Hims & HERS宣佈計劃以大約3100萬美元收購一個5030億美元的複合外包設施，以擴展其複合能力。董事會還授權了一項新的10000萬美元股票回購計劃，持續到2027年8月，此前完成了5000萬美元的計劃。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    樸荷生物科技
    PHH
    -- 12.790
    雷特控股
    RAY
    -- 2.040
    大樹雲
    DSY
    -- 1.100
    聯合利華(英國)
    UL
    -- 59.180
    Kenvue
    KVUE
    -- 23.700
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日